---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-031716"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:32:20.380617+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024

## Summary
- EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.
- IIS study: 6/12 CR (50%), 4/12 PR (33%), ORR 83%; no severe CRS; durable responses up to 23.2 months.
- Partnered with Imugene (ASX:IMU) to combine CF33-CD19t oncolytic virus with EB103 for solid tumors.
- Pipeline includes EB104 (CD19/CD22 dual-targeting) for lymphoma and EB201 for SLE (preclinical).

## SEC filing metadata
- accession: 0001213900-24-031716
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390024031716/0001213900-24-031716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390024031716/ea0203610-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-031716
- JSON: https://secwatch.observer/filing/0001213900-24-031716.json
- Plain text: https://secwatch.observer/filing/0001213900-24-031716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.